Replies to post #170491 on Biotech Values

[jq1234]

Well, Teva's internal projection on Copaxone profit for 2014 is 42% lower. I suppose it assumes generic will get approved in 2014:

http://www.pharmalive.com/what-copaxone-profits-yet-another-troubling-leak-at-teva

[Rocky3]

MNTA new 12-month intra-day high of $18.15.

And how many stocks are hitting all-time highs, with equal or higher moves this year? We can look at the SI contest list of the leaders and see many, many stocks with 100% moves this year. I am near the average and I have 4 up 100%+ - VPHM, GILD, JAZZ, and ENDP. VPHM is at the level from a buyout, but the other three are hugely above all historical values. JAZZ is up nearly 8,000% in five years.

MNTA has a long way to go to be near 10s of alternative biotech stocks. I still think that it is possible, but it surely has been a relative loser compared to the spectacular returns available in BIIB and many others.